宏观视角（含综合性分析报告、投融资、管线等涉及多类别领域的报告）
请复制链接至电脑/手机浏览器查阅
序号 | 发布单位 | 标题 | 链接 | 日期 | 备注 |
1 | 医药行业2026年中期投资策略：创新引领，多点开花 | https://pdf.dfcfw.com/pdf/H3_AP202605211822647898_1.pdf?1779385149000.pdf | 2026/5/19 | ||
2 | 招银国际 | 中国医药：AI有望改变创新药研发范式 | https://www.fxbaogao.com/view?id=5426274&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/19 | 需注册账号，每日限制次数阅读、收费下载 |
3 | 诚通证券 | 医药行业2025年及26Q1业绩总结：总体平稳，创新药产业链一枝独秀 | https://pdf.dfcfw.com/pdf/H3_AP202605191822449834_1.pdf?1779215947000.pdf | 2026/5/18 | |
4 | Capgemini | Orchestrating the agentic revolution across life sciences | https://www.capgemini.com/wp-content/uploads/2026/05/PoV_Agentic-AI-in-LS_May-2026.pdf | 2026/5/18 | |
5 | PitchBook | 新兴技术研究：生物医药风险投资趋势 | https://pdf.dfcfw.com/pdf/H3_AP202605171822382659_1.pdf?1779029444000.pdf | 2026/5/17 | |
6 | 开源证券 | 医药生物行业深度报告：技术进步驱动合成生物学行业快速发展 | https://pdf.dfcfw.com/pdf/H3_AP202605151822348368_1.pdf?1778865526000.pdf | 2026/5/15 | |
7 | 国信证券 | A股生物医药行业2025年报&2026一季报总结：创新药及产业链持续高景气 | https://pdf.dfcfw.com/pdf/H3_AP202605151822349409_1.pdf?1778867195000.pdf | 2026/5/15 | |
8 | 西南证券 | 医药行业2025年报及2026年一季报总结：CXO、创新药业绩保持较好增长 | https://pdf.dfcfw.com/pdf/H3_AP202605151822356556_1.pdf?1778880967000.pdf | 2026/5/15 | |
9 | 国家药监局药品审评中心 | 2025年度药品审评报告 | https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437 | 2026/5/13 | |
10 | Brand Finance | Healthcare 2026 The annual report on the most valuable and strongest pharma, medical devicesand healthcare services brands | https://www.fxbaogao.com/view?id=5413436&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/12 | 需注册账号，每日限制次数阅读、收费下载 |
11 | 国金证券 | 医药配套行业行业研究：CXO行业深度报告：内外需共振向上，新分子赋能行业持续扩容 | https://pdf.dfcfw.com/pdf/H3_AP202605141822300058_1.pdf?1778745470000.pdf | 2026/5/11 | |
12 | 上海证券 | 医药生物行业两会“十五五”专题报告：医改纵深推进，创新智慧引领 | https://pdf.dfcfw.com/pdf/H3_AP202605121822211821_1.pdf?1778601342000.pdf | 2026/5/11 | |
13 | 东莞证券 | 医药生物行业2025年及2026年一季度业绩综述：Q1板块业绩好转，关注细分景气方向 | https://pdf.dfcfw.com/pdf/H3_AP202605111822153075_1.pdf?1778511406000.pdf | 2026/5/11 | |
14 | 东吴证券 | 医药行业2025年度及2026Q1总结报告：创新药、CXO及科研服务高增长，受益于BD出海及国内回暖 | https://pdf.dfcfw.com/pdf/H3_AP202605091822102943_1.pdf?1778332051000.pdf | 2026/5/9 | |
15 | 摩熵咨询 | 2026年乳腺癌流行病学趋势及热门靶点药物市场表现洞察 | https://pdf.dfcfw.com/pdf/H3_AP202605121822189882_1.pdf?1778573055000.pdf | 2026/5/8 | |
16 | Capgemini | Life sciences engineering and R&D pulse 2026 | https://www.capgemini.com/wp-content/uploads/2026/05/lifesciences-erandd-pulse2026.pdf | 2026/5/7 | |
17 | 中邮证券 | 医药2025年报及2026一季报总结：创新药及产业链维持高景气 | https://pdf.dfcfw.com/pdf/H3_AP202605071822027216_1.pdf?1778168990000.pdf | 2026/5/7 | |
18 | 艾昆纬 | eCTD 4.0: Implementation Including Understanding of Regional Differences and Benefits | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/ectd-40-implementation-including-understanding-of-regional-differences-and-benefits.pdf | 2026/5/6 | |
19 | 国泰海通证券 | 大药诞生之自免系列二：技术迭代领跑自免3.0时代，2026密集催化迎产业变革 | https://www.fxbaogao.com/view?id=5403270&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/5/6 | 需注册账号，每日限制次数阅读、收费下载 |
20 | 中银证券 | 医药行业25年年报及26年一季报综述 | https://pdf.dfcfw.com/pdf/H3_AP202605061821983997_1.pdf?1778077070000.pdf | 2026/5/6 | |
21 | 国金证券 | 医药行业制药板块25年&26Q1业绩总结：赛道分化，创新药板块高速增长 | https://pdf.dfcfw.com/pdf/H3_AP202605051821973834_1.pdf?1778055077000.pdf | 2026/5/6 | |
22 | McKinsey | Targeted and timely: Curating aesthetic care for GLP-1 patients | https://www.mckinsey.com/industries/life-sciences/our-insights/targeted-and-timely-curating-aesthetic-care-for-glp-1-patients | 2026/5/1 | |
23 | 国金证券 | 医药健康行业研究：终端需求逐步复苏，看好全年景气度反转 | https://pdf.dfcfw.com/pdf/H3_AP202605051821967957_1.pdf?1777993833000.pdf | 2026/5/1 | |
24 | 欧洲疾病预防控制中心 | 百日咳2024年年度流行病学报告 | https://pdf.dfcfw.com/pdf/H3_AP202604301821820215_1.pdf?1777561156000.pdf | 2026/4/30 | |
25 | 中国电子信息产业发展研究院电子信息研究所 | 人工智能赋能生物制造研究 | https://pdf.dfcfw.com/pdf/H3_AP202604281821651609_1.pdf?1777366272000.pdf | 2026/4/28 | |
26 | 摩熵咨询 | 2026年肝癌流行病学趋势及热门靶点药物市场表现洞察 | https://pdf.dfcfw.com/pdf/H3_AP202605121822189872_1.pdf?1778571658000.pdf | 2026/4/28 | |
27 | 东方证券 | 医药生物行业动态跟踪：2026 ASCO国内公司重点研究前瞻-ASCO盛会将至，中国创新药强势突围 | https://www.fxbaogao.com/view?id=5387108&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/28 | 需注册账号，每日限制次数阅读、收费下载 |
28 | 国家药品不良反应监测中心 | 国家药品不良反应监测年度报告 （2025年） | https://www.cdr-adr.org.cn/center_news/202604/t20260427_51496.html | 2026/4/27 | |
29 | 国信证券 | 医药行业快评ASCO年会标题发布，多个国产创新药研究成果入选口头报告 | https://www.fxbaogao.com/view?id=5378942&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/26 | 需注册账号，每日限制次数阅读、收费下载 |
30 | 摩熵咨询 | 2025年中国临床试验数据洞察 | https://consult.pharnexcloud.com/report/detail/115171.html | 2026/4/22 | 需注册账号，每日限制次数下载 |
31 | 中国医药创新促进会 | PMRE in Asia Volume 1: Regulatory Environment Identification and Clarification of the Differences in Regulatory Environment between Asian Economies | https://hqiv.oss-cn-beijing.aliyuncs.com/static/s/ych/download/2026年亚洲医药市场与监管环境报告1：监管报告.pdf | 2026/4/21 | |
32 | 中国医药创新促进会 | PMRE in Asia Volume 2: Information on the Market Environments of Asian Economies | https://hqiv.oss-cn-beijing.aliyuncs.com/static/s/ych/download/2026年亚洲医药市场与监管环境报告2：市场报告.pdf | 2026/4/21 | |
33 | UBS AG | China Healthcare Marketing book - Biotech and CRO | https://www.fxbaogao.com/view?id=5369405&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/21 | 需注册账号，每日限制次数阅读、收费下载 |
34 | Capgemini | The resurgence of manufacturing: Reindustrialization of Europe and the US – 2026 | https://www.capgemini.com/wp-content/uploads/2026/04/2000426CRI_Reindustrialization-_Interactive-1-1.pdf | 2026/4/20 | |
35 | UBS AG | China Healthcare AACR 2026: Highlights from our biopharma coverage | https://www.fxbaogao.com/view?id=5366414&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/20 | 需注册账号，每日限制次数阅读、收费下载 |
36 | 国信证券 | 创新药盘点系列报告（26）：四大支柱后，HFrEF心衰领域还有哪些升级空间？ | https://pdf.dfcfw.com/pdf/H3_AP202604201821331457_1.pdf?1776697198000.pdf | 2026/4/20 | |
37 | 安永(中国)企业咨询 | 医药行业穿越盈利的迷雾：安永“本土药企盈利引擎”模型1.0——供应链与财务篇 | https://pdf.dfcfw.com/pdf/H3_AP202604171821280037_1.pdf?1776411232000.pdf | 2026/4/17 | |
38 | 中国食品药品检定研究院 | 国家药品抽检年报（2025） | https://www.nifdc.org.cn//nifdc/bshff/gjchj/gjchjtzgg/202604161331002003989.html | 2026/4/16 | |
39 | 上海证券 | 医药生物行业2026年春季投资策略：“跟随”到“引领”，花开终有时 | https://pdf.dfcfw.com/pdf/H3_AP202604171821285929_1.pdf?1776424025000.pdf | 2026/4/16 | |
40 | 欧洲制药工业协会联合会 | 医疗投资与成果：在中央和东欧 | https://pdf.dfcfw.com/pdf/H3_AP202604151821247436_1.pdf?1776325786000.pdf | 2026/4/16 | |
41 | 国泰海通证券 | 自免行业报告系列：从MNC重磅BD看自免赛道技术迭代：大药诞生之自免系列一：千亿自免赛道迎代际更迭，MNC加速抢滩下一代管线 | https://www.fxbaogao.com/view?id=5357289&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/16 | 需注册账号，每日限制次数阅读、收费下载 |
42 | 高盛 | GLOBAL HEALTHCARE: BIOTECHNOLOGY | https://www.fxbaogao.com/view?id=5358247&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/16 | 需注册账号，每日限制次数阅读、收费下载 |
43 | 德勤 | 借力中国创新生态，重塑全球竞争力——外资生物医药企业在中国的战略重构与增长路径 | https://www.deloitte.com/content/dam/assets-zone1/cn/zh/docs/industries/life-sciences-health-care/2026/deloitte-accessing-biopharma-innovation-in-china-zh-260409.pdf | 2026/4/15 | |
44 | UBS AG | Women's Health Innovation | https://www.fxbaogao.com/view?id=5355520&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/14 | 需注册账号，每日限制次数阅读、收费下载 |
45 | McKinsey | Shaping the future of Japan’s pharmaceutical operations | https://www.mckinsey.com/industries/life-sciences/our-insights/shaping-the-future-of-japans-pharmaceutical-operations | 2026/4/14 | |
46 | BERNSTEIN | US Pharma and Biotech: MGA in 2026 is running hot... Our top picks through year end | https://www.fxbaogao.com/view?id=5351234&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/13 | 需注册账号，每日限制次数阅读、收费下载 |
47 | OECD | The Health and Economic Benefits of Tackling Non-Communicable Diseases | https://www.fxbaogao.com/view?id=5346054&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/11 | 需注册账号，每日限制次数阅读、收费下载 |
48 | 高盛 | US Pharma-Charts We Are Watching | https://www.fxbaogao.com/view?id=5344564&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/9 | 需注册账号，每日限制次数阅读、收费下载 |
49 | 国信证券 | 海内外CXO行业2025年总结：投融资复苏，景气度向好 | https://pdf.dfcfw.com/pdf/H3_AP202604081821058818_1.pdf?1775653848000.pdf | 2026/4/8 | |
50 | Norstella | 2026年医药研发年度报告 | https://www.fxbaogao.com/view?id=5346130&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/7 | 需注册账号，每日限制次数阅读、收费下载 |
51 | 东方证券 | 减重专题报告：MNC管线完善，重点转向开发平台 | https://www.fxbaogao.com/view?id=5336348&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/5 | 需注册账号，每日限制次数阅读、收费下载 |
52 | OECD | Addressing the Costs and Care for Long COVID：THE LONG SHADOW OF THE PANDEMIC | https://www.fxbaogao.com/view?id=5335242&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/4 | 需注册账号，每日限制次数阅读、收费下载 |
53 | 禾开生物 | A+B (AI+BD)双重冲击下的自免新药研发新策略 | https://www.fxbaogao.com/view?id=5350432&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/4/3 | 需注册账号，每日限制次数阅读、收费下载 |
54 | 中国抗癌协会宫颈癌专业委员会 | 2025中国宫颈癌诊疗现状白皮书 | https://pdf.dfcfw.com/pdf/H3_AP202604031821004171_1.pdf?1775209886000.pdf | 2026/4/3 | |
55 | 头豹研究院 | 2026年中国牙周病治疗行业洞察报告：高发病率叠加低就诊率，牙周疾病年轻化如何解决？ | https://pdf.dfcfw.com/pdf/H3_AP202604141821195172_1.pdf?1776195951000.pdf | 2026/3/31 | |
56 | 上海科创银行 | 中国医疗健康行业资本市场趋势 | https://pdf.dfcfw.com/pdf/H3_AP202604101821108129_1.pdf?1775812969000.pdf | 2026/3/31 | |
57 | 艾昆纬 | Southeast Asia and Pakistan Overview: The Emerging Hub for Clinical Trial Scale Up | https://www.iqvia.com/-/media/iqvia/pdfs/asia-pacific/insight-brief/sea-and-pakistan-insight-brief.pdf | 2026/3/27 | |
58 | 广发证券 | 英矽智能(03696.HK)独特AI制药平台，加速创新药研发 | https://www.fxbaogao.com/view?id=5324638&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/26 | 需注册账号，每日限制次数阅读、收费下载 |
59 | 国金证券 | 医药健康行业研究：医疗产业链提价专题-原料药及耗材迎来提价契机，行业景气度有望回升 | https://pdf.dfcfw.com/pdf/H3_AP202603241820712595_1.pdf | 2026/3/23 | |
60 | 头豹研究院 | 2026年中国早泄治疗用药行业概览：当“快”不再是赞美，如何满足男性健康市场沉默的刚需？ | https://pdf.dfcfw.com/pdf/H3_AP202604011820958141_1.pdf?1775072672000.pdf | 2026/3/20 | |
61 | Parexel | New Medicines, Novel Insights: Accelerating the New Frontiers in Neuroscience An Executive Summary | https://www.fxbaogao.com/view?id=5309843&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/20 | 需注册账号，每日限制次数阅读、收费下载 |
62 | 山西证券 | 医药行业2026年投资策略：多层次支付体系持续完善，中国创新初现锋芒 | https://pdf.dfcfw.com/pdf/H3_AP202603191820642544_1.pdf?1773930438000.pdf | 2026/3/19 | |
63 | 欧洲疾病预防控制中心 | 莱姆病年度流行病学报告（2023年） | https://pdf.dfcfw.com/pdf/H3_AP202603191820651332_1.pdf?1773951242000.pdf | 2026/3/19 | |
64 | 华泰证券 | https://www.fxbaogao.com/view?id=5307722&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/18 | 需注册账号，每日限制次数阅读、收费下载 | |
65 | ITIF | Lessons From Europe’s Loss of Biopharma Leadership, and Its Attempts to Recov | https://www.fxbaogao.com/view?id=5307944&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/18 | 需注册账号，每日限制次数阅读、收费下载 |
66 | 中国银河证券 | 医药生物行业“十五五”规划纲要解读报告：以人为本，医疗健康系统性升级 | https://www.fxbaogao.com/view?id=5308823&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/15 | 需注册账号，每日限制次数阅读、收费下载 |
67 | WHO | Arenaviridae Research & Development Roadmap | https://cdn.who.int/media/docs/default-source/consultation-rdb/arenaviridae-r-d-roadmap.pdf?sfvrsn=f898cc59_3&download=true | 2026/3/12 | |
68 | 国泰海通证券 | 2026年医药产业政策展望：“两会”绘蓝图，“十五五”新征途 | https://www.fxbaogao.com/view?id=5298223&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/12 | 需注册账号，每日限制次数阅读、收费下载 |
69 | 国信证券 | 创新药盘点系列报告（25）：IgA肾病药物已进入商业化兑现期 | https://pdf.dfcfw.com/pdf/H3_AP202603121820524391_1.pdf?1773341960000.pdf | 2026/3/12 | |
70 | 东吴证券 | 创新药进入收获期，仿制药CRO/CDMO困境反转 | https://consult.pharnexcloud.com/report/detail/114791.html | 2026/3/12 | 需注册账号，每日限制次数下载 |
71 | 艾昆纬 | 推动精准肿瘤学发展：美国肿瘤标志物检测趋势 | https://pdf.dfcfw.com/pdf/H3_AP202603191820636906_1.pdf?1773912340000.pdf | 2026/3/9 | |
72 | 药智 | 2025年度中国医药领域专利发展分析报告 | https://db.yaozh.com/reportcenter/info/id/550.html | 2026/3/9 | 需提供信息查阅、下载 |
73 | 国泰海通证券 | AI制药持续进展，跨国药企布局加速 | https://www.fxbaogao.com/view?id=5291802&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/9 | 需注册账号，每日限制次数阅读、收费下载 |
74 | 万联证券 | 医药生物行业深度报告：投融资与出海双轮驱动，CXO迎来景气度修复与全球化新周期 | https://pdf.dfcfw.com/pdf/H3_AP202603091820422805_1.pdf?1773095033000.pdf | 2026/3/9 | |
75 | 信达证券 | 新兴生物技术专题报告：小核酸药物方兴未艾，海外创新与国内崛起共振 | https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf | 2026/3/9 | |
76 | 信达证券 | 临床CRO行业深度跟踪：供需关系改善，有望驱动订单量价齐升 | https://pdf.dfcfw.com/pdf/H3_AP202603091820404498_1.pdf?1773055030000.pdf | 2026/3/9 | |
77 | 国金证券 | 医药行业研究：靶蛋白降解：下一代颠覆性治疗范式迎来商业化元年 | https://pdf.dfcfw.com/pdf/H3_AP202603101820434538_1.pdf?1773128891000.pdf | 2026/3/6 | |
78 | 国泰海通证券 | 延续心血管优势，核酸药物递送加速破局 | https://www.fxbaogao.com/view?id=5286735&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/3/5 | 需注册账号，每日限制次数阅读、收费下载 |
79 | 头豹研究院 | 2026年过敏性鼻炎药物品牌推荐双效合一，快速通鼻 | https://pdf.dfcfw.com/pdf/H3_AP202603051820308917_1.pdf?1772741320000.pdf | 2026/3/5 | |
80 | 药智 | 2025年度重点医药政策盘点 | https://db.yaozh.com/reportcenter/info/id/544.html | 2026/3/5 | 需提供信息查阅、下载 |
81 | 埃森哲 | 从实验室到生产线 重新定义生物制药 | https://pdf.dfcfw.com/pdf/H3_AP202602281820143602_1.pdf?1772313511000.pdf | 2026/2/28 | |
82 | 病痛挑战公益基金会&沙利文 | 2026中国罕见病行业趋势观察报告 | https://www.fxbaogao.com/view?id=5283648&requestId=&query={"reportTypes":["12","13"]}&index=0&pid=&xid= | 2026/2/27 | 需注册账号，每日限制次数阅读、收费下载 |
83 | 浙商证券 | 临床前CRO系列专题报告（一）：实验猴供需缺口大，持续看好临床前CRO深度研究 | https://www.fxbaogao.com/view?id=5278312&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/27 | 需注册账号，每日限制次数阅读、收费下载 |
84 | 国信证券 | 海外制药企业2025Q4&全年业绩回顾：2026会是下一个BD大年吗？ | https://pdf.dfcfw.com/pdf/H3_AP202602271820085454_1.pdf?1772184151000.pdf | 2026/2/26 | |
85 | 国泰海通证券 | FXI/FXIa抑制剂行业研究报告：从靶点到管线，FXI引领抗凝产业新变革 | https://www.fxbaogao.com/view?id=5273273&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/25 | 需注册账号，每日限制次数阅读、收费下载 |
86 | 高盛 | Byte-ology: Quantifying AI’s value creation in drug development | https://www.fxbaogao.com/view?id=5272705&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
87 | 上海现代服务业联合会&荣续智库 | 医养康行业ESG白皮书 | https://www.fxbaogao.com/view?id=5274571&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
88 | Morgan Stanley | 北美生物制药行业观点更新 | https://www.fxbaogao.com/view?id=5272710&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/20 | 需注册账号，每日限制次数阅读、收费下载 |
89 | 新世纪评级 | 医药制造与流通行业2025年信用回顾与2026年展望 | https://www.fxbaogao.com/view?id=5274583&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/15 | 需注册账号，每日限制次数阅读、收费下载 |
90 | 药研社、CCHRPP | 2025年度全国注册类药物临床试验开展情况蓝皮书（上篇） | https://www.fxbaogao.com/view?id=5281581&requestId=2604133979136247&query=%7B%22keywords%22%3A%222025年度全国注册类药物临床试验开展情况蓝皮书%22%2C%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/13 | 需注册账号，每日限制次数阅读、收费下载 |
91 | McKinsey | Life sciences: Dealmaking gains momentum as strategic pressures intensify | https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-dealmaking-gains-momentum-as-strategic-pressures-intensify | 2026/2/13 | 需提供信息下载 |
92 | DRAKE STAR PARTNERS | 远程医疗：2025年回顾与2026展望 | https://pdf.dfcfw.com/pdf/H3_AP202602101819861840_1.pdf?1770801724000.pdf | 2026/2/11 | |
93 | 中诚信国际 | 中国医药制造行业展望 | https://pdf.dfcfw.com/pdf/H3_AP202602111819874195_1.pdf?1770818751000.pdf | 2026/2/11 | |
94 | 德勤 | 2026年生命科学行业展望：生命科学行业高管认为企业财务前景比较乐观，但需在复杂国际局势中增强韧性 | https://pdf.dfcfw.com/pdf/H3_AP202602091819838338_1.pdf?1770663694000.pdf | 2026/2/9 | |
95 | 艾昆纬 | 优化早期临床试验以实现快速、基 于证据的决策 | https://pdf.dfcfw.com/pdf/H3_AP202602111819871322_1.pdf?1770809000000.pdf | 2026/2/9 | |
96 | ITIF | Tracking R&D Leadership: US Advantage Narrowing as China Gains Groun | https://www.fxbaogao.com/view?id=5263576&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/9 | 需注册账号，每日限制次数阅读、收费下载 |
97 | 艾昆纬 | 中东非洲药品商业洞察（第三十八版） | https://pdf.dfcfw.com/pdf/H3_AP202602281820143624_1.pdf?1772313733000.pdf | 2026/2/9 | |
98 | 美国癌症协会 | 医药：癌症事实与数据2026 | https://pdf.dfcfw.com/pdf/H3_AP202602071819822659_1.pdf?1770565915000.pdf | 2026/2/8 | |
99 | 药智 | 2025年度全球医药交易分析报告 | https://db.yaozh.com/reportcenter/info/id/537.html | 2026/2/6 | 需提供信息查阅、下载 |
100 | 广州中康资讯 | 《中国创新药蓝皮书（2025）》报告第一章 | https://pdf.dfcfw.com/pdf/H3_AP202602061819815133_1.pdf?1770416780000.pdf | 2026/2/6 | |
101 | 海通国际 | 美国医药调研反馈：肿瘤、代谢、自免、中枢神经系统赛道推荐更新 | https://www.fxbaogao.com/view?id=5259033&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/6 | 需注册账号，每日限制次数阅读、收费下载 |
102 | 西南证券 | 创新药专题：中国声音响彻2026年JPM大会 | https://pdf.dfcfw.com/pdf/H3_AP202602061819806370_1.pdf?1770389935000.pdf | 2026/2/6 | |
103 | 国泰海通证券 | 美国医药调研及JPM大会后反馈 | https://www.fxbaogao.com/view?id=5257867&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/2/5 | 需注册账号，每日限制次数阅读、收费下载 |
104 | 头豹研究院 | 2025年中国生物创新药市场跟踪报告：司美格鲁肽2025年第一季度市场回顾 | https://pdf.dfcfw.com/pdf/H3_AP202602041819774404_1.pdf?1770239567000.pdf | 2026/2/4 | |
105 | 智药局 | 2025 AI制药行业研究报告 | https://mp.weixin.qq.com/s/vqYQG9S2OJ-PtbaoRAa58A | 2026/2/4 | 需提供信息获取 |
106 | 药智 | 2025年度全球新药研发进展 | https://db.yaozh.com/reportcenter/info/id/535.html | 2026/2/2 | 需提供信息查阅、下载 |
107 | 信达证券 | “政策引导&技术支持”助力AI医疗崛起，蚂蚁阿福或成C端应用范例 | https://pdf.dfcfw.com/pdf/H3_AP202601301818576386_1.pdf?1769780721000.pdf | 2026/1/28 | |
108 | 摩熵咨询 | 2025全球罕见病行业发展报告：政策演进、市场趋势与领先企业布局 | https://pdf.dfcfw.com/pdf/H3_AP202601281818514005_1.pdf?1769635872000.pdf | 2026/1/26 | |
109 | 中邮证券 | 医药生物行业：国家统计局公布各项经济与人口数据，65岁及以上人口占比进一步提升 | https://pdf.dfcfw.com/pdf/H3_AP202601261818423652_1.pdf?1769439930000.pdf | 2026/1/26 | |
110 | 国信证券 | 医药生物行业2026年投资策略：关注创新出海，重视新技术方向 | https://pdf.dfcfw.com/pdf/H3_AP202601271818448366_1.pdf?1769501702000.pdf | 2026/1/26 | |
111 | 开源证券 | 北交所策略专题报告：药械出海获顶层设计加速，掘金北交所、新三板专精特新稀缺资产 | https://www.fxbaogao.com/view?id=5239334&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/25 | 需注册账号，每日限制次数阅读、收费下载 |
112 | PitchBook | The Chinese Biopharma Landscape: Where New Assets Are Born（新兴技术研究：中国生物医药格局：新资产诞生之地） | https://pdf.dfcfw.com/pdf/H3_AP202602071819822655_1.pdf?1770566304000.pdf | 2026/1/23 | |
113 | FDA | Advancing Health Through Innovation: New Drug Therapy Approvals 2025 | https://www.fda.gov/media/190705/download?attachment | 2026/1/23 | |
114 | 广州洞犀企业咨询 | 口腔产业投融资观察（2025） | https://pdf.dfcfw.com/pdf/H3_AP202601231818320268_1.pdf?1769185770000.pdf | 2026/1/23 | |
115 | 信达证券 | CXO行业跟踪报告：高景气度有望持续，JPM大会更新要点解读 | https://pdf.dfcfw.com/pdf/H3_AP202601231818303539_1.pdf?1769156127000.pdf | 2026/1/22 | |
116 | 摩熵咨询 | IgA肾病药物研发全景及已上市药物市场竞争格局报告 | https://consult.pharnexcloud.com/report/detail/114355.html | 2026/1/22 | 需注册账号，每日限制次数下载 |
117 | 中邮证券 | AI制药：从降本增效到分子创新，数据生产构筑长期壁垒 | https://pdf.dfcfw.com/pdf/H3_AP202601221818269607_1.pdf?1769094912000.pdf | 2026/1/22 | |
118 | 西南证券 | 药品专题报告：2025年药品BD出海总结 | https://pdf.dfcfw.com/pdf/H3_AP202601211818190934_1.pdf?1768988442000.pdf | 2026/1/21 | |
119 | WHO | WHO's response to the global mpox outbreak | https://cdn.who.int/media/docs/default-source/documents/health-topics/monkeypox/who-s-response-to-the-global-mpox-outbreak-donor-report-august-2025-september-2025.pdf?sfvrsn=e0c3fb48_3&download=true | 2026/1/21 | |
120 | 艾昆纬 | An Agentic AI-Powered Consumer Health Revolution: Scenarios on How Foundation Models and AI Agents Could Transform Discovery, Trust, and Commerce | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/an-agentic-ai-powered-consumer-health-revolution.pdf | 2026/1/20 | |
121 | Vi Labs | State of AI in Wellness 2026 | https://www.fxbaogao.com/view?id=5232069&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/20 | 需注册账号，每日限制次数阅读、收费下载 |
122 | UBS AG | Q-Series Redux: Global Medtech Dragons through the gate; entering a new era ofcompetition | https://www.fxbaogao.com/view?id=5227146&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/15 | 需注册账号，每日限制次数阅读、收费下载 |
123 | 西南证券 | CXO跟踪报告：关注新分子的成长性与国内景气度修复的传导 | https://pdf.dfcfw.com/pdf/H3_AP202601151817082480_1.pdf?1768510551000.pdf | 2026/1/15 | |
124 | 硕远咨询 | 2025年中国母婴医疗服务行业市场研究报告 | https://www.fxbaogao.com/view?id=5223219&requestId=2601194187293593&query=%7B%22keywords%22%3A%222025年中国母婴医疗服务行业市场研究报告%22%2C%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/14 | 需注册账号，每日限制次数阅读、收费下载 |
125 | 药智 | 2025年度中国上市药品分析报告 | https://db.yaozh.com/reportcenter/info/id/528.html | 2026/1/14 | 需提供信息查阅、下载 |
126 | McKinsey | Capturing value from customer-centric medtech services | https://www.mckinsey.com/industries/life-sciences/our-insights/capturing-value-from-customer-centric-medtech-services | 2026/1/14 | 需提供信息下载 |
127 | 艾昆纬 | Clinical Trials in Tuberculosis Across Asia Pacific: Navigating Challenges and Exploring Solutions | https://www.fxbaogao.com/view?id=5241337&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/13 | 需注册账号，每日限制次数阅读、收费下载 |
128 | 药智 | 2025年度CDE药审分析报告 | https://db.yaozh.com/reportcenter/info/id/526.html | 2026/1/13 | 需提供信息查阅、下载 |
129 | Capgemini | Smart bet,only option,or both? Biopharma R&Dturns to Al. | https://www.capgemini.com/wp-content/uploads/2026/01/140126CRI_Gen-AI-in-Lifesciences-_Final-interactive-1.pdf | 2026/1/13 | |
130 | 头豹研究院 | 2025年中国带状疱疹疫苗行业洞察报告：免疫需求扩容+政策红利加持背景下，百克生物率先获批，国产疫苗如何承接市场？ | https://pdf.dfcfw.com/pdf/H3_AP202602241819998923_1.pdf?1771961794000.pdf | 2026/1/13 | |
131 | 艾昆纬 | A New, AI-Augmented Horizon for Safety and Pharmacovigilance:Expert Predictions for 2026 | https://www.fxbaogao.com/view?id=5224741&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/12 | 需注册账号，每日限制次数阅读、收费下载 |
132 | 艾昆纬 | 肺动脉高压临床试验教育者的演进与影响 | https://pdf.dfcfw.com/pdf/H3_AP202601071816825683_1.pdf | 2026/1/8 | |
133 | 万联证券 | 2025FDA新药全景：创新疗法与市场变革——医药生物行业跟踪报告 | https://pdf.dfcfw.com/pdf/H3_AP202601081816835695_1.pdf?1767860577000.pdf | 2026/1/8 | |
134 | 艾昆纬 | Trustworthy AI/ML for Patient Analytics and Research | https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/trustworthy-aiml-for-patient-analytics-and-research---final.pdf | 2026/1/7 | |
135 | 联合资信评估 | 医药制造行业2026年度信用风险展望 | https://pdf.dfcfw.com/pdf/H3_AP202601071816798126_1.pdf?1767808943000.pdf | 2026/1/7 | |
136 | McKinsey | The emerging epicenter: Asia’s role in biopharma’s future | https://www.mckinsey.com/industries/life-sciences/our-insights/the-emerging-epicenter-asias-role-in-biopharmas-future#/ | 2026/1/7 | 需提供信息下载 |
137 | 太平洋证券 | 医药行业2026年度策略报告：创新药产业链景气度持续提升 | https://pdf.dfcfw.com/pdf/H3_AP202601061815853167_1.pdf?1767687989000.pdf | 2026/1/6 | |
138 | 爱建证券 | 2026年医药行业投资策略：创新出海新征程，寻找需求新增量 | https://pdf.dfcfw.com/pdf/H3_AP202601061815857250_1.pdf?1767688824000.pdf | 2026/1/6 | |
139 | 招商证券 | 全球医药、医疗行业：2026年关注慢病迭代经营质量和现金流 | https://www.fxbaogao.com/view?id=5215406&requestId=&query=%7B%22reportTypes%22%3A%5B%2212%22%2C%2213%22%5D%7D&index=0&pid=&xid= | 2026/1/5 | 需注册账号，每日限制次数阅读、收费下载 |
140 | 北京蛋黄科技 | 2025创新药及供应链年度创新白皮书：分化加速，行业回归平台与产品价值 | https://pdf.dfcfw.com/pdf/H3_AP202601041814560749_1.pdf?1767525627000.pdf | 2026/1/4 | |
141 | 太平洋证券 | 2026年度医药行业投资策略：聚焦创新，共赴新程 | https://pdf.dfcfw.com/pdf/H3_AP202601041814519850_1.pdf?1767519175000.pdf | 2026/1/4 | |
142 | 艾昆纬 | 中风领域的发展：关键管道和临床试验见解 | https://pdf.dfcfw.com/pdf/H3_AP202601041814560829_1.pdf?1767526172000.pdf | 2026/1/4 |
